Our Strategy

We partner with entrepreneurs to create companies that have a significant impact on patients’ lives. Participating at all stages of development and across all sectors, we take a broad strategic approach to investing in life sciences.

Typical Investments

Investment size$15-$30m in total per company
OwnershipMajority or minority
GeographyPrimarily US and Europe
Holding period3-8 years
SectorsBiotherapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics, instrumentation

BROAD STRATEGIC APPROACH

Within the life sciences market we participate in a wide range of opportunities spanning therapeutics, medical devices, diagnostics, instrumentation and software. We invest in seed stage projects, technology platforms, preclinical and clinical assets as well as approved and marketed products. Supporting private and public companies, we aim to partner with the most innovative entrepreneurs to address significant unmet needs in healthcare.

Discover the Strategies

Covering programmes and companies at many different stages of development, our diverse strategies provide us with unusually broad insights into the key factors for success in biotechnology.

"I have found Abingworth to be extremely supportive in positioning Paratek for success. In addition to providing finance and executive leadership, their deep knowledge of the sector and extensive network have proven to be invaluable in creating value for the company today and in the future."

Evan Loh, President of Paratek Pharmaceuticals

"I feel fortunate to have Abingworth as an investor in Wilson Therapeutics. Their in-depth knowledge of drug development in combination with being very well connected in the life science industry adds great value to our company."

Jonas Hansson, CEO of Wilson Therapeutics

"Working with Abingworth to build CRISPR Therapeutics is a pleasure. They are incredibly supportive in shaping the company, which aims to lead the highly dynamic and competitive environment of gene editing."

Rodger Novak, Chairman of CRISPR Therapeutics

"Abingworth was the original lead investor in SFJ and has since made 5 additional investments in SFJ related companies. Working together to maximize the full potential growth and sustainability of SFJ, we have formed a true partnership with the Abingworth team."

Robert DeBenedetto, President and CEO of SFJ Pharmaceuticals

"Abingworth are a very hands-on investor who bring their extensive experience in the life sciences sector to the board table. They have been a great support and used their connections to source exceptional individuals to join our growing company."

Allison Jeynes-Ellis, CEO of Avillion